Home > Highly Selective JAK1 Inhibitor / New Drug SHR0302 Base Ointment of Reistone Biopharma Having Been Approved for Clinical Trial to Treat Vitiligo
Highly Selective JAK1 Inhibitor / New Drug SHR0302 Base Ointment of Reistone Biopharma Having Been Approved for Clinical Trial to Treat Vitiligo
Recently, Reistone Biopharma Company Limited received the Notice of Clinical Trial approved and issued by NMPA, and was approved to carry out the clinical trial of SHR0302 base ointment to be intended for vitiligo.
Vitiligo is a common acquired skin depigmentation disorder, and its main symptom is local or generalized skin leukoderma caused by melanin deficiency of skin mucosa. The incidence is between 0.1% and 2.0% throughout the world. Domestic epidemiological survey found that the prevalence is 0.56%. This disease seriously affects the appearance and normal social activities of the patients, causing a serious psychological burden on the patients. Glucocorticoids and phototherapy are mainly used for treatment of vitiligo, while the long-term systematic use will have great side effects for the former and may cause malignant skin diseases for the latter.
SHR0302 is a highly selective, small molecule JAK1 kinase inhibitor that is introduced from Hengrui Pharmaceutical by Reistone Biopharma, with its dosage forms of tablet and ointment currently under clinical development for multiple indications. SHR0302 base ointment is administered topically, and expected to be a safe and effective drug in the treatment of vitiligo.
SHR0302 base ointment is also being subject to the indication research for atopic dermatitis in addition to vitiligo. Besides, SHR0302 oral tablets are being studied for the indications of ulcerative colitis, Crohn’s disease, atopic dermatitis, alopecia areata, etc.
About Reistone Reistone Biopharma Company Limited is a clinical stage biopharmaceutical company, focusing on the global development of innovative drugs for skin diseases caused by autoimmune diseases and immune disorders. Founded in April 2018 and headquartered in Zhangjiang, Shanghai, the company now has about 100 employees in China and the United States. Reistone Biopharma has introduced 4 products from Hengrui Pharmaceutical, currently running 4 phase II studies and 2 phase I studies globally. For more information on Reistone Biopharma, please visit www.reistonebio.com.